雷珠单抗注射液联合复方血栓通胶囊对年龄相关性黄斑变性患者临床疗效研究

Clinical Effect of Leizhu Monoclonal Antibody Injection combined with Compound Xueshuantong Capsule on age-related macular degeneration

目的:探讨雷珠单抗联合复方血栓通胶囊对年龄相关性黄斑变性患者外周血血管内皮生长因子、眼压及视力变化的影响。方法:收集我院收治的年龄相关性黄斑变性患者60例,随机分为实验组和对照组,每组各30例,对照组给予雷珠单抗玻璃体腔内注射,实验组在对照组基础上给予复方血栓通胶囊每月1次,均治疗3个月,治疗结束后,对所有患者的血清VEGF、CRP含量、CMT、CNV水平、眼压和视力进行检测。结果:治疗后,与对照组比较,实验组患者的血清VEGF含量明显较低,差异具有统计学意义(P<0.05);实验组患者的血清CRP含量明显明显较低(P<0.05);实验组患者的CMT、CNV水平明显较低(P<0.05);实验组患者的视力(logMAR)及IOP水平明显较低(P<0.05)。结论:实验结果表明针对年龄相关性黄斑变性患者,雷珠单抗联合复方血栓通胶囊可以降低患者外周血VEGF、CRP的含量,并且还可以减少CMT、CNV的含量,达到降低眼部血压,改善视力的作用,对临床有指导意义。

Objective: To investigate the effects of Leizhuman injection combined with compound Xueshuantong Capsule on the changes of vascular endothelial growth factor, intraocular pressure and visual acuity in patients with age-related macular degeneration. Methods: 60 patients with age-related macular degeneration in our hospital were randomly divided into treatment group and control group, 30 cases in each group. The control group was given intravitreal injection of Leizhumab injection. The treatment groupwas given compound Xueshuantong capsule once a month on the basis of the control group. All patients were treated for 3 months. After treatment, the control group was given intravitreal injection of Leizhumab. Serum levels of vascular endothelial growth factor, CRP, CMT, CNV, intraocular pressure and visual acuity were measured. Results: After treatment, compared with the control group, the serum levels of vascular endothelial growth factor in the treatment groupwere significantly lower (P<0.05);the serum CRP levels in the treatment groupwere significantly lower (P<0.05);the levels of CMT, CNV in the treatment group were lower (P<0.05);The visual acuity (logMAR) and IOP level were significantly lower (P<0.05). Conclusion: The experimental results show that for age-related macular degeneration patients, Leizhumab injection combined with compound Xueshuantong capsule ophthalmic injection can reduce the levels of vascular endothelial growth factor and CRP in peripheral blood, and also reduce the contents of CMT and CNV, so as to lower the ocular blood pressure and improve the visual acuity. It has guiding significance for clinical practice.